These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 24408055

  • 1. Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer.
    Gao YH, Zhang X, An X, Cai MY, Zeng ZF, Chen G, Kong LH, Lin JZ, Wan DS, Pan ZZ, Ding PR.
    Strahlenther Onkol; 2014 Feb; 190(2):158-64. PubMed ID: 24408055
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.
    Gao YH, An X, Sun WJ, Cai J, Cai MY, Kong LH, Lin JZ, Liu GC, Tang JH, Wu XJ, Chen G, Pan ZZ, Ding PR.
    J Surg Oncol; 2014 Apr; 109(5):478-82. PubMed ID: 24288203
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL, Meng WJ, Shu P, Deng XB, Wu B, Jiang D, Zhuang H, Shen YL, Zhou ZG, Wang ZQ, Wang X.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr 25; 22(4):349-356. PubMed ID: 31054549
    [Abstract] [Full Text] [Related]

  • 6. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.
    Zhu J, Liu F, Gu W, Lian P, Sheng W, Xu J, Cai G, Shi D, Cai S, Zhang Z.
    Radiat Oncol; 2014 Mar 07; 9():70. PubMed ID: 24606870
    [Abstract] [Full Text] [Related]

  • 7. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.
    Zhu J, Gu W, Lian P, Sheng W, Cai G, Shi D, Cai S, Zhang Z.
    Radiat Oncol; 2013 May 29; 8():130. PubMed ID: 23718210
    [Abstract] [Full Text] [Related]

  • 8. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer.
    Dellas K, Höhler T, Reese T, Würschmidt F, Engel E, Rödel C, Wagner W, Richter M, Arnold D, Dunst J.
    Radiat Oncol; 2013 Apr 15; 8():90. PubMed ID: 23587311
    [Abstract] [Full Text] [Related]

  • 9. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.
    Nogué M, Salud A, Vicente P, Arriví A, Roca JM, Losa F, Ponce J, Safont MJ, Guasch I, Moreno I, Ruiz A, Pericay C, AVACROSS Study Group.
    Oncologist; 2011 Apr 15; 16(5):614-20. PubMed ID: 21467148
    [Abstract] [Full Text] [Related]

  • 10. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
    Zhao L, Bai C, Shao Y, Guan M, Jia N, Xiao Y, Qiu H, Zhang F, Yang T, Zhong G, Chen S.
    Cancer Lett; 2011 Nov 28; 310(2):134-9. PubMed ID: 21782322
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study.
    Kamiya T, Uehara K, Nakayama G, Ishigure K, Kobayashi S, Hiramatsu K, Nakayama H, Yamashita K, Sakamoto E, Tojima Y, Kawai S, Kodera Y, Nagino M, Nagoya Surgical Oncology Group and the Chubu Clinical Oncology Group.
    Eur J Surg Oncol; 2016 Jun 28; 42(6):829-35. PubMed ID: 26968228
    [Abstract] [Full Text] [Related]

  • 13. Pilot study of intense neoadjuvant chemoradiotherapy for locally advanced rectal cancer: retrospective review of a phase II study.
    Xu BH, Chi P, Guo JH, Guan GX, Tang TL, Yang YH, Chen MQ, Song JY, Feng CY.
    Tumori; 2014 Jun 28; 100(2):149-57. PubMed ID: 24852858
    [Abstract] [Full Text] [Related]

  • 14. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
    Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, Vera R, Escudero P, Maurel J, Marcuello E, Mengual JL, Saigi E, Estevan R, Mira M, Polo S, Hernandez A, Gallen M, Arias F, Serra J, Alonso V.
    J Clin Oncol; 2010 Feb 10; 28(5):859-65. PubMed ID: 20065174
    [Abstract] [Full Text] [Related]

  • 15. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
    Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG.
    Int J Radiat Oncol Biol Phys; 2012 Mar 15; 82(4):1367-75. PubMed ID: 21775070
    [Abstract] [Full Text] [Related]

  • 16. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
    Yu X, Wang QX, Xiao WW, Chang H, Zeng ZF, Lu ZH, Wu XJ, Chen G, Pan ZZ, Wan DS, Ding PR, Gao YH.
    Cancer Commun (Lond); 2018 May 21; 38(1):24. PubMed ID: 29784042
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
    Chiorean EG, Sanghani S, Schiel MA, Yu M, Burns M, Tong Y, Hinkle DT, Coleman N, Robb B, LeBlanc J, Clark R, Bufill J, Curie C, Loehrer PJ, Cardenes H.
    Cancer Chemother Pharmacol; 2012 Jul 21; 70(1):25-32. PubMed ID: 22610353
    [Abstract] [Full Text] [Related]

  • 19. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, Tebbutt N, Hill M, Ross PJ, Massey A, Oates J.
    J Clin Oncol; 2006 Feb 01; 24(4):668-74. PubMed ID: 16446339
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.